Hepatitis C virus: Morphogenesis, infection and therapy

doi:10.4254/wjh.v10.i2.186

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 10, Issue 2

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (30479)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-10) series, Tables (1-4) series.

Item

Count

PDF

2927

WORD

516

HTML

23651

Figures (1-10)

615

Tables (1-4)

180

Sum=27889

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1249

Download

1341

Sum=2590

Feb 27, 2018 (publication date) through Apr 23, 2024

Times Cited of This Article

Times Cited (99)

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Hepatol. Feb 27, 2018; 10(2): 186-212
Published online Feb 27, 2018. doi: 10.4254/wjh.v10.i2.186

Table 1 Overview of the size of hepatitis C virus proteins

Protein	No. of aa	aa position n ref. seq.	MW of protein, kDa
Core immature	191	1-191	23
Core mature	174	1-174	21
F protein of ARF protein	126-161		Approximately 16-17
E1	192	192-383	35
E2	363	384-746	70
p7	63	747-809	7
NS2	217	810-1026	21
NS3	631	1027-1657	70
NS4A	54	1658-1711	4
NS4B	261	1712-1972	27
NS5A	448	1973-2420	56
NS5B	591	2421-3011	66

No. of aa: Number of amino acid; MW: Molecular weight; kDa: KiloDalton; ref.seq.: Reference sequence (HCV strain H77 ; accession number NC_0041).

Table 2 Commercially available hepatitis C virus RNA detection assays

Assay	Distributor	Technology	Detection limits (IU/mL)	Genotypes	Approval status
Qualitative HCV RNA detection assays
Amplicor^TM HCV 2.0	Roche molecular Systems	PCR	50	All	FDA, CE
Versant^TM HCV	Siemens Medical Solutions Diagnostics	TMA	5-10	All	FDA, CE
Quantitative HCV RNA detection
Amplicor^TM HCV Monitor 2.0	Roche molecular Systems	PCR	500 to approximately 5.10⁵	All	CE
HCV SuperQuant^TM	National Genetics institute	PCR	30 to 10⁷	All	U.S only
Versant^R HCV RNA 3.0	Siemens Medical Solutions Diagnostics	bDNA	615 to 8.10⁶	All	FDA, CE
Cobas^R AmpliPrep/High pure system/Cobas^R TaqMan^R	Roche molecular Systems	Real-time PCR	15 to 10⁷	All	FDA, CE
Abbot RealTime^TM HCV	Abbot Diagnostics	Real-time PCR	10 to 10⁷	All	FDA, CE
Artus HCV QS-RGQ assay	Qiagen	Real-time PCR	34 to 10⁸	All	CE
Versant^RR HCV 1.0 kPCR assay	Siemens	Real-time PCR	10 to approximately 10⁷	-	CE

HCV: hepatitis C virus; TMA: Transcription-mediated amplification of RNA; bDNA: Branched DNA hybridization assay.

Table 3 Selected directly acting antiviral agents and host targeting agents in the pipeline[63]

Drugs name	Company	Target/active site	Phase
NS3/4A protease inhibitors
Vaniprevir (MK-7009)	Merck	Active site/macrocyclic	III
Voxilaprevir GS-9857	Gilead	Active site	III
Glecaprevir (ABT-493)	Abbvie	Active site	III
IDX21437	Idenix	Active site	II
Sovaprevir (ACH-1625)	Achillion	Active site/macrocyclic?	II
Nucleoside analog NS5B polymerase inhibitors (NI)
MK-3682 (formerly IDX20963)	Merck	Active site	II
ACH-3422	Achillion/Janssen	Active site	II
Non- Nucleoside analog NS5B polymerase inhibitors (NNI)
Beclabuvir (BMS-791325)	Bristol-Myers Squib	NNI site 1/Thumb 1	III
Setrobuvir (ANA598)	Anadys/Roche	NNI site 4?/palm 1	II
NS5A inhibitors
BMS-824393	Bristol-Myers Squibb	NS5A protein	II
PPI-461	Presidio	NS5A protein	II
PPI-668	Presidio	NS5A protein	II
Pibrentasvir (ABT-530)	Abbvie	NS5A protein	III
ACH-2928	Achillion	NS5A protein	I
Ruzasvir (MK-8408)	Merck	NS5A protein	II
Host targeting agents
SCY-635	Scynexis	Cyclophilin inhibitor	II
Miravirsen	Santaris	miRNA122 antisense NA	II
RG-101-	Regulus	miRNA122 antisense NA	II
TT-0034	Tacere Therapeutics	RNA interference with HCV	II

Table 4 Selected directly acting antiviral agents and host targeting agents whose development has been stopped or temporarily halted[63]

Drugs name Company Target/Active site
NS3 /4A protease inhibitors
Ciluprevir BILN 2061	Boehringer Ingelheim	Active site/macrocyclic
Narlaprevir (SCH900518)	Schering-Plough	Active site/linear
PHX1766	Pheromix	Active site
Danoprevir (R7227)	Roche/InterMune	Active site/macrocyclic
Faldaprevir (BI201335)	Boehringer Ingelheim	Active site/linear
Telaprevir (VX-950)	Vertex	Withdrawn
Boceprevir (SCH503034)	Merck	Withdrawn
Nucleoside analogue NS5B polymerase inhibitors (NI)
Valopicitabine (NM283)	Idenix/Novartis	Active site
R1626	Roche	Active site
Mericitabine (R7128)	Roche/Pharmasset	Active site
GS-938	Gilead	Active site
IDX184	Idenix	Active site
Non-nucleoside NS5B polymerase inhibitors (NNI)
BILB 1941	Boehringer Ingelheim	NNI site 1/thumb
MK-3281	Merck	NNI site 1/thumb 1
VX-759	Vertex	NNI site 2/thumb 2
VX-222	Vertex	NNI site 2/thumb 2
VX-916	Vertex	NNI site 2/thumb 2
ABT-072	AbbVie	NNI site 3/palm 1
HCV-796	ViroPharma/Wyeth	NNI site 4/palm 2
Filibuvir (PF-00868554)	Pfizer	NNI site 2/thumb 2
IDX375	Idenix	NNI site 4/palm 2
Tegobuvir (GS-9190)	Gilead	NNI site 4/palm 2
GS-9669	Gilead	NNI site 3/palm 1
Deleobuvir	Böhringer	NNI site 3/palm 1
Host targeting agents
NIM811	Novartis	Cyclophilin inhibitor
Alisporivir (Debio-025)	Novartis	Cyclophilin inhibitor

Citation: Morozov VA, Lagaye S. Hepatitis C virus: Morphogenesis, infection and therapy. World J Hepatol 2018; 10(2): 186-212
URL: https://www.wjgnet.com/1948-5182/full/v10/i2/186.htm
DOI: https://dx.doi.org/10.4254/wjh.v10.i2.186